Advances in neuropharmacological rehabilitation for brain dysfunction

References

• Chavany J. A. Rôle des causes occasionelles dans le détérminisme du ramolissement cérébral (reflections thérapeutiques à le propos). Pratique médicale franćaise 1928; 7: 285–295
   Google Scholar
• Sciclounoff F. L'acetylcholine dans le traitement de l'ictus hemiplégique. Presse médicale 1934; 42: 1140
   Google Scholar
• Sutton R. L., Weaver M. S., Feeney D. M. Drug-induced modifications of behavioural recovery following cortical trauma. Journal of Head Trauma Rehabilitation 1987; 2: 50–58
   Google Scholar
• Feeney D. M., Sutton R. L. Pharmacotherapy for recovery of function after brain injury. CRC Critical Reviews in Neurobiology 1987; 3: 135–197
   Google Scholar
• Gilman S., Newman S. W. Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology. F.A. Davis, Philadelphia 1987
   Google Scholar
• Seigel G. J., Agranoff R. W. Basic Neurochemistry, B. W. Agranoff, R. W. Albers, P. B. Molinoff. Raven Press, New York 1989; 203–332
   Google Scholar
• Cooper J. R., Bloom F. E., Roth R. H. The Biochemical Basis of Neuropharmacology. Oxford University Press, New York 1986
   Google Scholar
• Bradley P. B. Introduction to Neuropharmacology. Wright, Boston 1989
   Google Scholar
• Hyman S. E. Recent developments in neurobiology: Part II. Neurotransmitter receptors and psychopharmacology. Psychosomatics 1988; 29: 254–263
   PubMedGoogle Scholar
• Gershanik O., Heikkila R. E., Duvoisin R. C. Behavioural correlations of dopamine receptor activation. Neurology 1983; 33: 1489–1492
   PubMed Web of Science ®Google Scholar
• Koller W. C., Herbster G. D1 and D2 Dopamine receptor mechanisms in dopaminergic behaviours. Clinical Neuropharmacology 1989; 11: 221–231
   Google Scholar
• American Hospital Formulary Service. Drug Information, G. K. McEvoy. American Society of Hospital Pharmacists, Bethesda, MD 1989
   Google Scholar
• Cedarbaum J. M. Clinical pharmacokinetics of anti-Parkinsonian drugs. Clinical Pharmacokinetics 1987; 13: 141–178
   PubMed Web of Science ®Google Scholar
• Berg M. J., Ebert B., Willis D. K., et al. Parkinsonism–Drug treatment: Part I. Drug Intelligence and Clinical Pharmacy 1987; 21: 10–21
   PubMedGoogle Scholar
• Gualtieri T., Chandler M., Coons T. B., et al. Amantadine: a new clinical profile for traumatic brain injury. Clinical Neuropharmacology 1989; 12: 258–270
   PubMed Web of Science ®Google Scholar
• Peterson P. L., Saad J., Nigro M. A. The treatment of Friedreich's ataxia with amantadine hydrochloride. Neurology 1988; 38: 1478–1480
   PubMed Web of Science ®Google Scholar
• Bak I., Hassler R., Kim J., et al. Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioural changes. Journal of Neural Transmission 1972; 33: 4561
   Google Scholar
• Gualtieri C. T. Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury. Brain Injury 1988; 2: 101–129
   PubMedGoogle Scholar
• Physicians Desk Reference. Edward R. Barnhart, Ordell, N.J. 1990
   Google Scholar
• Sommi R. W., Crismon M. L., Bowden C. L. Fluoxetine: a Serotonin-specific, second-generation antidepressant. Pharmacotherapy 1987; 7: 001–015
   PubMed Web of Science ®Google Scholar
• Kastenholz K. V., Crismon M. L. Buspirone, a novel nonbenzodiazepine anxiolytic. Clinical Pharmacy 1984; 3: 600–607
   PubMedGoogle Scholar
• Eison A. S., Temple D. L. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. American Journal of Medicine 1986; 80: 1–9
   PubMed Web of Science ®Google Scholar
• Newton R. E., Marunycz J. D., Alderdice M. T., et al. Review of side-effect profile of buspirone. American Journal of Medicine 1986; 80: 17–21
   PubMed Web of Science ®Google Scholar
• Slutsker L., Hoesly F. C., Miller L., et al. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. Journal of the American Medical Association 1990; 264: 213–217
   PubMed Web of Science ®Google Scholar
• Mendels J. Clinical experience with serotonin reuptake: inhibiting antidepressants. Journal of Clinical Psychiatry 1987; 48: 26–30
   PubMed Web of Science ®Google Scholar
• Bleck T. P., Klawans H. L. Convulsive disorders: mechanisms of epilepsy and anticonvulsant action. Clinical Neuropharmacology 1990; 13: 121–128
   PubMed Web of Science ®Google Scholar
• Rolls E. T. Psychopharmacology and food. The Nuerophysiology of Feeding, M. Sandler, T. Silverstone. British Association for Psychopharmacology Monograph No. 7, New York 1985; 1–16
   Google Scholar
• Morley J. E. An approach to the development of drugs for appetite disorders. Neuropsychobiology 1989; 21: 22–30
   PubMedGoogle Scholar
• Childs A. Naltrexone in organic bulimia: a preliminary report. Brain Injury 1987; 1: 49–55
   PubMedGoogle Scholar
• Sandyk R., Lacona R. P. Post-traumatic cerebellar syndrome: response to L-tryptophan. International Journal of Neuroscience 1989; 47: 301–302
   PubMed Web of Science ®Google Scholar
• Trouillas P., Brudon F., Adeleine P. Improvement of cerebellar ataxia with levoratory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Archives of Neurology 1988; 45: 1217–1222
   PubMed Web of Science ®Google Scholar
• Manyam B. V. Recent advances in the treatment of cerebellar ataxias. Clinical Neuropharmacology 1986; 9: 508–516
   PubMedGoogle Scholar
• Bonuccelli U., Nuti A., Cei G., et al. Oral thyrotropin-releasing hormone treatment in inherited ataxias. Clinical Neuropharmacology 1988; 11: 520–528
   PubMedGoogle Scholar
• Rudy T. A. Pathogenesis of fever associated with cerebral trauma and intracranial hemorrhage. Thermoregulatory mechanisms and their therapeutic implications. 4th International Symposium on the Pharmacology of Thermoregulation Oxford. Karger, Basel 1979; 75–81
   Google Scholar
• Lipton J. M., Clark W. G. Neurotransmitters in temperature control. Annual Review of Physiology 1986; 48: 613–632
   PubMed Web of Science ®Google Scholar
• Yamawaki S., Lai H., Horita A. Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 383–388
   PubMedGoogle Scholar
• Zasler N. D., McNeny R. Neuropharmocologic rehabilitation following traumatic brain injury via dopamine agonists. Archives of Physical Medicine and Rehabilitation 1989; 70: A12–A13
   Google Scholar
• Bontke C. F., Zasler N. D., et al. Dopamine agonist pharmacotherapy for hyperpyrexia following severe traumatic brain injury, in preparation
   Google Scholar
• Fleet W. S., Valenstein E., Watson R. T., et al. Dopamine agonist therapy for neglect in humans. Neurology 1987; 37: 1765–1770
   PubMed Web of Science ®Google Scholar
• Koller W. C., Wong G. F., Lang A. Post-traumatic movement disorders: review. Movement Disorders 1989; 4: 20–36
   PubMed Web of Science ®Google Scholar
• Katz D. I. Movement disorders following traumatic head injury. Journal of Head Trauma Rehabilitation 1990; 5(1): 86–90
   Google Scholar
• Biary N., Cleeves L., Findley L., et al. Post-traumatic tremor. Department of Neurology 1989; 1: 103–106
   Google Scholar
• Ellison P. H. Propranolol for severe post-head injury action tremor. Neurology 1978; 28: 197–199
   PubMedGoogle Scholar
• Samie M. R., Selhorst J. B., Koller W. C. Post-traumatic midbrain tremor. Neurology 1990; 40: 62–66
   PubMed Web of Science ®Google Scholar
• Hallett M., Lindsey J. W., Adelstein B. D., et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985; 35: 1374–1377
   PubMed Web of Science ®Google Scholar
• Zdonczyk D., Royse V., Roller W. C. Nicotine and tremor. Clinical Neuropharmacology 1988; 11: 282–286
   PubMed Web of Science ®Google Scholar
• Sohn D. G., Hoerning E., Kaplan P. E. Carbidopa-levodopa therapy for movement disorders. Archives of Physical Medicine and Rehabilitation 1987; 68: 745–746
   PubMedGoogle Scholar
• Santosh L., Merbtiz C. P., Grip J. C. Modification of function in head-injured patients with Sinemet. Brain Injury 1988; 2: 225–233
   PubMedGoogle Scholar
• Eames P. The use of Sinemet and bromocriptine. Brain Injury 1989; 3: 319–320
   PubMedGoogle Scholar
• Della S. S., Mazzini L. Post-traumatic extrapyramidal syndrome: case report. Servizio di Neuropsicologia Clinica, Centro Medico De Veruno, Fondazione Clinica del. Lavoro. Italian Journal of Neurological Science 1990; 1: 65–69
   Google Scholar
• Carter C. J., Pycock C. J. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat. Brain Research 1980; 192: 163–76
   PubMed Web of Science ®Google Scholar
• Stewart J. T. Akathisia following traumatic brain injury: treatment with bromocriptine. Journal of Neurology, Neurosurgery and Psychiatry 1989; 52: 1200–1203
   PubMed Web of Science ®Google Scholar
• Adler L. A., Reiter S., Corwin J., et al. Neuroleptic-induced akathisia: propranolol versus benztropine. Bioligical Psychiatry 1988; 23: 211–213
   PubMedGoogle Scholar
• Watanabe K., Kuroiwa Y., Toyokura Y. Epilepsia partialis continua; epileptogenic focus in motor cortex and its participation in transcortical reflexes. Archives of Neurology 1984; 41: 1040–1044
   PubMedGoogle Scholar
• Obeso J. A., Artieda J., Rothwell J. C., et al. The treatment of severe action myoclonus. Bran 1989; 112: 765–777
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Fahn S. Movement Disorders 2. Butterworths, London 1987
   Google Scholar
• Jankovic J., Pardo R. Segmental myoclonus, clinical and pharmacologic study. Archives of Neurology 1986; 43: 1025–1031
   PubMedGoogle Scholar
• Roig M., Monserrat L., Gallart A. Carbamazepine: an alternative drug for the treatment of nonhereditary chorea. Department of Pediatrics 1988; 82: 492–495
   PubMed Web of Science ®Google Scholar
• Robin J. J. Paroxysmal choreoathetosis following head injury. Annals of Neurology 1977; 2: 447–448
   PubMedGoogle Scholar
• Richardson J. C., Howes J. L., Celniski M. J., et al. Kinesigenic choreoathetosis due to brain injury. Canadian Journal of Neurological Sciences 1987; 14: 626–628
   PubMedGoogle Scholar
• Bontke C. F. Medical complications related to traumatic brain injury. State of the Art Reviews: Physical Medicine and Rehabilitation, L. J. Horn, D. N. Cope. Hanley and Belfus, Philadelphia 1989
   Google Scholar
• Temkin N. R., Dikmen S. S., Wilensky A. J., et al. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. New England Journal of Medicine 1990; 323: 497–502
   PubMed Web of Science ®Google Scholar
• Kuhl D. A., Boucher B. A., Muhlbauer M. S. Prophylaxis of post-traumatic seizures. DICP Annals of Pharmacotherapy 1990; 24: 277–285
   PubMedGoogle Scholar
• Wyler A. R., Ray M. W. Anticonvulsant prophylaxis against post-traumatic seizures. Contemporary Neurosurgery 1985; 7: 1–6
   Google Scholar
• Glenn M. B., Wroblewski B. Anticonvulsants for prophylaxis of post-traumatic seizures. Journal of Head Trauma Rehabilitation 1986; 1: 73–74
   Google Scholar
• O'Shanick G. J., Zasler N. D. Neuropsychopharmacological approaches to traumatic brain injury. Community Integration Following Traumatic Brain Injury, J. Kreutzer, P. Wehman. Paul H. Brookes, Baltimore 1990; 15–27
   Google Scholar
• Pellock J. M. Editorial: who should receive prophylactic antiepiliptic drug following head injury?. Brain Injury 1989; 3: 107–108
   PubMedGoogle Scholar
• Gaskins J. D., Holt R. J., Posteinick A. Nondosage-dependent valproic acid-induced hyperammonemia and coma. Clinical Pharmacology 1984; 3: 313–316
   PubMedGoogle Scholar
• Jones G. L., Matsuo F., Baringer J. R., et al. Valproic acid-associated encephalopathy. Western Journal of Medicine 1990; 153: 199–202
   PubMedGoogle Scholar
• Marescaux C., Warter J. M., Michelletti G., et al. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982; 23: 297–305
   PubMedGoogle Scholar
• Collaborative GROUP FOR EPIDEMIOLOGY OF Epilepsy. Adverse reactions to anti-epileptic drugs: a multicenter survey of clinical practice. Epilepsia 1986; 27: 323–330
   PubMedGoogle Scholar
• Thompson P. J., Trimble M. R. Comparative effects of anticonvulsant drugs on cognitive functioning. British Journal of Clinical Practice 1982b; 18: 154–156
   Google Scholar
• Trimble M. R. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28: S37–S45
   Web of Science ®Google Scholar
• Meador K. J., Loring D. W., Huh K., et al. Comparative cognitive effects of anticonvulsants. Nuerology 1990; 40: 391–394
   PubMed Web of Science ®Google Scholar
• Levy R. H., et al. Antiepileptic Drugs. Raven Press, New York 1989
   Google Scholar
• Crismon M. L., Childs A., Wilcox R. E., et al. The effect of bromocriptine on speech dysfunction in patients with diffuse brain injury (akinetic mutism). Clinical Neuropharmacology 1988; 11: 462–466
   PubMed Web of Science ®Google Scholar
• Bachman D. L., Morgan A. The role of pharmacotherapy in the treatment of aphasia: preliminary result. Aphasiology 1988; 2: 225–228
   Web of Science ®Google Scholar
• Albert M. L., Bachman D. L., Morgan A., et al. Pharmacotherapy for aphasia. Neurology 1988; 38: 877–879
   PubMed Web of Science ®Google Scholar
• Bieger D., Giles S. A., Hockman C. H. Dopaminergic influences on swallowing. Neuropharmacology 1977; 16: 245–252
   Google Scholar
• Bieger D., Weerasuriya A., Hockman Ch. H. The emetic action of L-dopa and its effect on the swallowinag reflex in the at. Journal of Neural Transmission 1978; 42: 87–98
   PubMedGoogle Scholar
• Rucker K. S., Zasler N. D., Narasimhachari N., et al. Resolution of swallowing disorder with L-dopa and evaluation of CSF neurotransmitters in brain injury. Archives of Physical Medicine and Rehabilitation 1988; 69: 734
   Google Scholar
• Biary N., Pimental P. A., Langenberg P. W. A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology 1988; 38: 255–258
   PubMed Web of Science ®Google Scholar
• Baratz R., Mesulam M. M. Adult-onset stuttering treated with anticonvulsants. Archives of Neurology 1981; 38: 132
   PubMedGoogle Scholar
• Kreutzer J., Zasler N. D. Psychosexual consequences of traumatic brain injury: methodology and preliminary findings. Brain Injury 1989; 3: 177–186
   PubMedGoogle Scholar
• Zasler N. D., Horn L. J. Rehabilitative management of sexual dysfunction. Journal of Head Trauma Rehabilitation 1990; 5: 14–24
   Google Scholar
• Segraves R. T. Drugs and desire. Sexual Desire Disorders, S. R. Leiblum, R. C. Rosen. Guilford, New York 1988; 328–333
   Google Scholar
• Morales A., Surridge D. H.C., Marshall P. G., et al. Nonhormonal pharmacological treatment of organic impotence. Journal of Urology 1982; 128: 45–47
   PubMed Web of Science ®Google Scholar
• Kockott G. Sexual disorders. Clinical Psychopharmacology, Part 2, H. Hipius, G. Winokur. Excerpta Medica-Princeton, Lawrenceville, N.J. 1983; 345–352
   Google Scholar
• Zasler N. D. The role of the physiatrist in vocational rehabilitation for persons with traumatic brain injury. Vocational Rehabilitation for Persons with Traumatic Brain Injury, P. Wehman, J. S. Kreutzer. Aspen, Rockville, MD 1990; 71–87
   Google Scholar
• McConaghy N., Blaszczynski A., Kidson W. Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica 1988; 77: 199–206
   PubMed Web of Science ®Google Scholar
• Lehne G. K. Brain damage and paraphilia: treated with medroxyprogesterone acetate. Sexuality and Disability 1986; 7: 145–157
   Google Scholar
• Berlin F. S., Meinecke C. F. Treatment of sex offenders with antiandrogenic medication: conceptualization, review of treatment modalities, and preliminary findings. American Journal of Psychiatry 1981; 137: 782–790
   Google Scholar
• Stewart J. T. Carbamazepine treatment of a patient with Kluver-Bucy syndrome. Journal of Clinical Psychiatry 1985; 46: 496–497
   PubMedGoogle Scholar
• Zasler N. D. Sexuality issues after traumatic brain injury. Sexuality Update 1988; 1: 1–3
   Google Scholar